Drugs /

monalizumab

Back to Drugs List

Overview

NCI Definition [1]:
A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.

Clinical Trials

View Clinical Trials for monalizumab

Monalizumab has been investigated in 8 clinical trials, of which 6 are open and 2 are closed. Of the trials investigating monalizumab, 2 are phase 1/phase 2 (2 open), 5 are phase 2 (3 open), and 1 is phase 3 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for monalizumab clinical trials.

Colorectal carcinoma, hypopharyngeal squamous cell carcinoma, and laryngeal squamous cell carcinoma are the most common diseases being investigated in monalizumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Monalizumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Monalizumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating monalizumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
nn-8765, iph-2201, monalizumab, iph2201, nn8765, anti-nkg2a monoclonal antibody iph2201, nn8765-3658, immunoglobulin g4-kappa, anti-(homo sapiens klrc1 (killer cell lectin-like receptor subfamily c member 1, nkg2-a, nkg2a, cd159a, cd94)), humanized monoclonal antibody
Drug Target(s) [2]:
KLRC1
NCIT ID [1]:
C120208

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.